<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018223</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18766</org_study_id>
    <nct_id>NCT03018223</nct_id>
  </id_info>
  <brief_title>Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT</brief_title>
  <official_title>A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if a combination of drugs (these are called:
      cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better
      against graft vs. host disease (GVHD) after receiving a hematopoietic cell transplant from a
      related partially matched (haploidentical) donor. As part of the treatment for their blood
      cancer, participants need a hematopoietic cell transplantation (HCT) to improve their chances
      of cure. In any HCT, after the stem cell infusion is given, a combination of drugs is needed
      to prevent GVHD and facilitate acceptance of the graft.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)</measure>
    <time_frame>100 days post hematopoietic cell transplant (HCT)</time_frame>
    <description>Cumulative incidence of grade II-IV acute GVHD by day 100 after HCT. Acute GVHD organ staging and assessment of overall grade will use standard consensus criteria. The cumulative incidence of acute and chronic GVHD will be estimated, considering malignancy relapse and non-relapse death as competing risk events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Cumulative incidence and severity of chronic GVHD by 1 year. Chronic GVHD diagnosis and severity scoring will follow National Institutes of Health (NIH) Consensus guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 1 year post HCT</time_frame>
    <description>Overall survival defined as time from transplant to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 1 year post HCT</time_frame>
    <description>Progression-free survival defined as the minimum time interval from transplant to relapse/recurrence, to death or to last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Acute Leukemia in Remission</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-HCT Conditioning, HCT, GVHD Prophylaxis.
Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.
Peripheral blood hematopoietic cell transplantation
Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.
Growth factor support: G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>Fludara, Oforta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>Busulfex, Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation (TBI)</intervention_name>
    <description>Reduced intensity conditioning: 200 centigray (cGy) on day -1.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Hematopoietic Cell Transplantation (HCT)</intervention_name>
    <description>On day 0, patients will receive a peripheral blood hematopoietic cell graft.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>cell graft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (SIR)</intervention_name>
    <description>GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-colony stimulating factor (G-CSF)</intervention_name>
    <description>Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is &gt; 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.</description>
    <arm_group_label>Conditioning/HCT/GVHD Prophylaxis</arm_group_label>
    <other_name>Neupogen, Filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient Participants:

          -  Age: Must be older than 18 years, no upper age limit.

          -  Karnofsky performance status: Full intensity conditioning, 80-100%; reduced intensity
             conditioning, 60-100%.

          -  Vital organ function: a) Cardiac: Left ventricular ejection fraction must be &gt; 45%
             assessed by multigated acquisition (MUGA) scan or echocardiogram. No myocardial
             infarction within 6 months of transplant evaluation. b) Pulmonary: forced expiratory
             volume at one second (FEV1), forced vital capacity (FVC), and adjusted diffusing
             capacity of the lungs for carbon monoxide (DLCO) must be ≥ 50% of predicted values. c)
             Liver: Transaminases (AST, ALT) less than 2 times upper limit of normal values. d)
             Kidney: Estimated creatinine clearance ≥ 50 cc/min.

          -  Signed informed consent.

          -  Included disease conditions and remission status: a) Acute leukemia in First Complete
             Remission (CR1) or second/subsequent CR. b) Chronic myeloid leukemia, primary
             myelofibrosis, chronic myelomonocytic leukemia. c) Int-2 or high risk myelodysplastic
             syndrome (MDS). d) Hodgkin lymphoma beyond CR1 with chemosensitive disease, Stable
             Disease (SD) may be included if no mass &gt;3 cm. e) Non-Hodgkin lymphoma in high risk
             CR1 or subsequent CR (by clinical, cytogenetic or molecular criteria), primary
             induction failure (PIF) or relapsed with chemosensitive disease. SD may be included if
             no mass &gt;3 cm. f) Multiple myeloma in CR/Very Good Partial Response (VGPR).

        Donor Participants:

          -  Per Moffitt Cancer Center (MCC) Blood and Marrow Transplant (BMT) program practices,
             an allele level matched (8/8 HLA A, B, C and DR) sibling or unrelated donor is
             preferred. If a matched donor is not found, mismatched unrelated or haploidentical
             donors may be considered.

          -  If a haploidentical donor is considered, parents, children, full siblings and in
             selected cases, extended family, will have high resolution typing at the MCC HLA
             laboratory. A familiar haploidentical donor is chosen among those who share at least
             one HLA-A, B, C, DRB1 and DQB1 haplotype with the patient.

          -  Patient will be screened for antibodies targeting mismatched HLA antigens in potential
             haploidentical donors (donor specific antibodies, DSA). Antibody screen and
             confirmatory testing using Luminex single antigen-bead test will be done.

          -  Among several potential donors, will choose in order of priority: a) Matched
             cytomegalovirus (CMV) immunoglobulin G (IgG) serologic status between donor and
             recipient. b) ABO blood group system-matched donor preferred, then minor ABO mismatch,
             then major ABO mismatch. c) Younger donor preferred: child, then sibling, and then
             parent. d) For male recipient, male donor will be preferred. Avoid mother as a donor
             unless no other choices.

        Exclusion Criteria:

        Patient Participants:

          -  Uncontrolled active bacterial, viral, fungal infection.

          -  Prior allogeneic HCT.

          -  Unwilling to comply with study requirements.

          -  Active, progressive or advanced disease based on diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelli Bejanyan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Urdiales</last_name>
    <phone>813-745-1218</phone>
    <email>maria.urdiales@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelli Bejanyan, M.D.</last_name>
    <phone>813-745-6008</phone>
    <email>nelli.bejanyan@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nelli Bejanyan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Alsina, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Betts, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Davila, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Fernandez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Kelley, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Kharfan-Dabaja, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farhad Khimani, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Locke, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asmita Mishra, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiga Nishihori, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ocho-Bayona, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lia Perez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Pidala, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute leukemia in CR</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Non-Hodgkin lymphoma in high risk</keyword>
  <keyword>Graft vs. Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Hematopoietic cell transplant (HCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

